Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
An Open-label Single Ascending Dose and Randomized Double-Masked, Ranibizumab Controlled, Safety, Tolerability, and Efficacy Study of Intravitreal LMG324 in Subjects With Neovascular Age-Related Macular Degeneration
Sponsor: Alcon Research
Terminated
Management decision
Other terminated trials from Alcon Research
Other Age-related Macular Degeneration (AMD) trials with similar outcome
This PHASE1/PHASE2 trial investigates Age-related Macular Degeneration (AMD) and is currently terminated or withdrawn. Alcon Research leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE1_PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Terminated PHASE1_PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
Status: Suspended → Terminated
-
Feb 2017 — Nov 2017 [monthly]
Suspended PHASE1_PHASE2
Status: Terminated → Suspended
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alcon Research
- Novartis Institutes for BioMedical Research
For direct contact, visit the study record on ClinicalTrials.gov .